









Markets
/
Stocks
/
nasdaq-pali
/

Palisade Bio Inc

PALI

1.640USD

+0.140+9.33%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

14.96MMarket Cap

LossP/E TTM



Palisade Bio Inc

1.640

+0.140+9.33%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Palisade Bio Inc

Currency: USD Updated: 2026-02-06

Key Insights

Palisade Bio Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 142 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.17.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Palisade Bio Inc's Score

Industry at a Glance

Industry Ranking

142 / 392

Overall Ranking

287 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Palisade Bio Inc Highlights

StrengthsRisks

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

Undervalued

The company’s latest PE is -0.79, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 68.41M shares, increasing 49.82% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.12M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.49.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

13.167

Target Price

+777.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Palisade Bio Inc is 6.83, ranking 202 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.83

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.66

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.70

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Palisade Bio Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Palisade Bio Inc is 6.71, ranking 235 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.79, which is -554.87% below the recent high of 3.59 and -52.43% above the recent low of -1.20.

Score

Industry at a Glance

Previous score

6.71

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 142/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Palisade Bio Inc is 8.33, ranking 132 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 21.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

13.167

Target Price

+777.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Palisade Bio Inc

PALI

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Palisade Bio Inc is 4.46, ranking 348 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.96 and the support level at 1.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.22

Change

0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.031

Sell

RSI(14)

45.095

Neutral

STOCH(KDJ)(9,3,3)

33.532

Neutral

ATR(14)

0.146

Low Volatility

CCI(14)

-54.346

Neutral

Williams %R

62.745

Sell

TRIX(12,20)

-0.951

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.598

Buy

MA10

1.638

Buy

MA20

1.746

Sell

MA50

1.904

Sell

MA100

1.762

Sell

MA200

1.262

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

12.05M

Octagon Capital Advisors LP

9.57M

Commodore Capital LP

9.33M

Squadron Capital Management LLC

8.25M

Point72 Asset Management, L.P.

Star Investors

7.59M

RA Capital Management, LP

7.12M

Deep Track Capital LP

6.43M

The Vanguard Group, Inc.

Star Investors

62.11K

+1892.56%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Palisade Bio Inc is 2.82, ranking 195 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.58. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.